"David Noakes, CEO of Immuno Biotech Ltd, was a company CEO for many years.
"GcMAF is essential to the immune system, he felt it was vital GcMAF is supplied to people who could no longer make their own. He went into production in December 2010, and Immuno Biotech Ltd's new laboratory was opened in 2011. His laboratories have designed assay methods that use GcMAF to destroy live cancer cells to test the activity of the GcMAF produced. These are filmed through microscopes, and have themselves become the subject of research papers.
"David Noakes, CEO of Immuno Biotech Ltd, was a company CEO for many years and a campaigner for human rights. In July 2009 he was given the word GcMAF at a lecture while working in Belgium, and read three research papers on it; he found the proofs incontrovertible. GcMAF is essential to the immune system, he felt it was was vital GcMAF is supplied to people who could no longer make their own. He was concerned that, 20 years after it was discovered, no one appeared to be making it available to the public, and resolved to do so. He read the remaining 32 mainly cancer/GcMAF research papers, and was fortunate to form links with eminent scientists in Holland, the UK and Italy. He went into production in December 2010 using shared laboratory facilities, and Immuno Biotech Ltd's own laboratory was opened in 2011." 
Resources and articles
- Nobuto Yamamoto
- His company's bank account was closed in 2014 
- Jeffrey Bradstreet 
- Brian Gerrish
- Marco Ruggiero
- gcmafconference David Noakes, organizational web page, accessed July 14, 2014.